Delena M - Search Results

1

Effects of subcutaneous recombinant IL-2 on humoral immunity in advanced cancer-patients.

Casamassima A, Guida M, Latorre A, Abbate I, Triantafillou V, Musci M, Delena M. Casamassima A, et al. Among authors: delena m. Int J Oncol. 1993 Aug;3(2):171-6. doi: 10.3892/ijo.3.2.171. Int J Oncol. 1993. PMID: 21573344

2

Long-term subcutaneous recombinant interleukin-2 as maintenance therapy: biological effects and clinical implications.

Guida M, Abbate I, Casamassima A, Musci MD, Latorre A, Lorusso V, Correale M, De Lena M. Guida M, et al. Cancer Biother. 1995 Fall;10(3):195-203. doi: 10.1089/cbr.1995.10.195. Cancer Biother. 1995. PMID: 8547958 Clinical Trial.

3

Subcutaneous recombinant interleukin-2 plus alpha interferon and vinblastine in metastatic renal cell carcinoma.

Guida M, Latorre A, Selvaggi F, Ditonno P, Lorusso V, Mastria A, Delena M. Guida M, et al. Among authors: delena m. Int J Oncol. 1997 Mar;10(3):487-91. doi: 10.3892/ijo.10.3.487. Int J Oncol. 1997. PMID: 21533401

4

Evaluation of phagocytic-activity in neoplastic patients treated with subcutaneous recombinant IL-2.

Abbate I, Guida M, Musci M, Casamassima A, Latorre A, Addabbo L, Dragone C, Cattedra M, Correale M, Delena M. Abbate I, et al. Among authors: delena m. Int J Oncol. 1993 Oct;3(4):603-6. doi: 10.3892/ijo.3.4.603. Int J Oncol. 1993. PMID: 21573406

5

Subcutaneous ril-2 in advanced melanoma and kidney carcinoma.

Delena M, Guida M, Casamassima A, Addabbo L, Abbate I, Correale M, Musci M, Lorusso V, Latorre A, Mastria A. Delena M, et al. Int J Oncol. 1992 Jul;1(2):181-9. doi: 10.3892/ijo.1.2.181. Int J Oncol. 1992. PMID: 21584529

6

Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different nosological entities?

Guida M, Casamassima A, Abbate I, Paradiso A, Zito A, Marzullo F, Lorusso V, Timurian A, Cramarossa A, De Lena M. Guida M, et al. Tumori. 1994 Oct 31;80(5):370-7. doi: 10.1177/030089169408000512. Tumori. 1994. PMID: 7839469 Review.

7

Modification of soluble immunological parameters during treatment with interleukin-2.

Abbate I, Correale M, Musci MD, Guida M, Dragone CD, De Santis M, De Lena M. Abbate I, et al. Int J Biol Markers. 1993 Oct-Dec;8(4):227-32. doi: 10.1177/172460089300800405. Int J Biol Markers. 1993. PMID: 8138662

8

Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma.

Guida M, Latorre A, Mastria A, De Lena M. Guida M, et al. Eur J Cancer. 1996 Apr;32A(4):730-3. doi: 10.1016/0959-8049(95)00662-1. Eur J Cancer. 1996. PMID: 8695281

9

Epithelial ovarian cancer: second and third line chemotherapy (review).

Latorre A, De Lena M, Catino A, Crucitta E, Sambiasi D, Guida M, Misino A, Lorusso V. Latorre A, et al. Int J Oncol. 2002 Jul;21(1):179-86. Int J Oncol. 2002. PMID: 12063566 Review.

10

Accelerated neoadjuvant chemotherapy of non-small cell lung cancer (NSCLC).

Lorusso V, Carpagnano F, Dirienzo G, Catino A, Cisternino M, Guida M, Brandi M, Latorre A, Parisi S, Ricco R, Delena M. Lorusso V, et al. Among authors: delena m. Int J Oncol. 1996 Apr;8(4):675-80. doi: 10.3892/ijo.8.4.675. Int J Oncol. 1996. PMID: 21544412

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

176 results

Search Page

Filters